2012-2017 assessment report the development of the vaccine industry analysis and investment potential ------------------------------------ Report No. 104516 [publishing] industry Institute of Economic Research [publication time delivery report format paper version: 6500 yuan [electronic version]: 6800 yuan [paper + electronic: 7000 yuan [in] October 2012 】 Speedpost / E-MAIL [Order Tel] 010-56036118 010-52876950 [green channel] 15313900551 [Customer Service: QQ】 2697021579 【Contact】 Li Jun [corporate website] http://www.cyjjyjy.com/yiyaobaogao/ zhongyao/104516.html (Click to view text) [Contents] 1 Overview 1 Section vaccine definition and classification analysis of the first part of the development of the industry the first chapter of the development of the vaccine industry, the definition of the vaccine two, three types of vaccines, vaccine 3 4 Section II of the vaccine industry characteristics defined 5-economic characteristics of the industry, the major industry segments, the structure of the industry chain analysis of the history and evolution of 6 Section III vaccine 7, two of the early history of the vaccine, the transition period of the vaccine 10 three, Shi Kuibo Sons Research Laboratory earlier studies 11 IV 12 V. bacterial vaccines, viral vaccines 13 VI, inactivated Polio vaccine 14 seven, eight live vaccines to prevent childhood diseases 15 measles vaccine nine 16 10 16 of the mumps vaccine, anti-hepatitis vaccine discovery and development of 17 the second chapter of the global vaccine market development analysis of 21 first section of the global vaccine industry characteristics analysis of 21 global vaccine two become the new growth of the pharmaceutical industry hot 21 intensified 22, the global vaccine market monopoly, more intense competition in the global vaccine market 22 four global infectious disease vaccines preventive effect analysis 24 a remarkable 24 Section II of the global vaccine market development, the status of the global vaccine market analysis of 24 global vaccine enterprise Development Analysis 25 Third, the global vaccine enterprise chasing a hot 27 four multinationals coveted Chinese vaccine market 28 Section III global vaccine market segmentation analysis of 29 global cancer vaccines market development 30 Second, the development of the global influenza vaccine market condition 30 Third, the global avian flu vaccine research progress 31 4 33 five global breast cancer the vaccine market research progress, the global humans and animals birds universal avian flu vaccine development progress of 34 six AIDS vaccine research progress 35 July, 2012 of lung cancer vaccine development 35 VIII 2012 the world's most advanced malaria vaccine candidate into phase III testing environment for the development of 36 of Chapter III of the vaccine industry analysis environment for economic development of 37 Section I Analysis 37, 2012 China's macroeconomic indicators Analysis 37, 2012 judgment and prediction of China's macro-economic situation of 67 Section II of the policy and regulatory environment Analysis 76, 2012 76, 2012 industry industrial policy vaccine industry policy environment analysis its affect 78, 2012 put on the agenda of the vaccine strategic reserve 78 third section technology development environment analysis 81, 81 Second, of the status of domestic vaccine technology the 2012 vaccine technology development analysis 85 of resistant protective dose of the live vaccine R & D and application status 86 Section IV of the biopharmaceutical industry development analysis 88 a biological the development of the pharmaceutical industry 88 Chinese biopharmaceutical industry market share and development potential of 89 three biopharmaceutical industry concentration and competition analysis 90 IV 90 five independent development of China's biopharmaceutical biopharmaceutical production technology Analysis capacity analysis, China's vaccine production and 92 six, the main problem faced by the Chinese biopharmaceutical industry 92 seven, the biopharmaceutical industry environment PEST Analysis 94 Chapter Chinese vaccine market development analysis of the vaccine industry 96 Section I Analysis 96 a overview of the state 96 two 2012 vaccine market size analysis 96 Third, the revitalization of China's vaccine industry ripe 97 four, the golden era of the development of China's vaccine industry 98 five among the world's three major influenza vaccine production base in China 99 six heavily promote 7 100 R & D powerhouse of the vaccine by the use of a large country towards our efforts to vaccine R & D and production power forward the development of China's vaccine industry in 2012 101 Section II Analysis 102 102 two 2012 National Center construction progress of novel vaccine, the vaccine industry in 2012 structure seeking to upgrade change 103, the export tax rebate rate increase in 2012 to help the vaccine exports growth of 104 Section III Chinese vaccine market problems analysis 105 a 2 Nanjin 105 the Chinese underground vaccine market, vaccine delivery safety issues of concern 105 three the road of industrialization of aquaculture vaccines remain to promote the 106 Section IV Vaccine classification management analysis 109 a 109 two, the status quo of China's Vaccine classification management, our implementation of vaccine category management problems faced 110 three, China to strengthen vaccine response category management measures 110 Section V of the Chinese vaccine market analysis and thinking 112, 112 two of the characteristics of the vaccine market, vaccine market analysis 112 three, four vaccine market changes direction 112 112 The second part of the Development of the Chinese vaccine industry sub-industry The fifth chapter of the development of analysis (H1N1) influenza virus vaccine market analysis 114 114 Section I of influenza vaccine market, influenza viruses Overview 114 Second, the influenza vaccination benefits 118 119 four influenza vaccination rates in China, China's first approved China already has the introduction of a dedicated flu vaccine for the elderly 119 five human avian influenza vaccine production conditions 119 Section II of the 2012 global influenza A H1N1 influenza virus vaccine market in 120 countries stepping up development of two H1N1 influenza virus vaccine 120 the U.S. $ 1 billion U.S. dollars to fund the influenza vaccine R & D 122 III, South Korea successfully developed influenza vaccine will be mass-produced in China in 2012 122 Section III (H1N1) influenza virus vaccine market analysis 123 a domestic influenza vaccine manufacturing companies stepped up preparations response to a pandemic 123 two off the assembly line 124 of the first H1N1 vaccine, H1N1 vaccine production enterprises to the list of 124, five national flu vaccine plan reserves of 125, China intends to reserve before the National Day of 1% of the total population the flu vaccine 126 Chapter other key vaccine market analysis 127 Section I of the Children's Vaccine Market Analysis 127, 127 two of the children's vaccine market status of provinces and cities expand children's vaccines in 2012, plans 127 three ,2010-2013 childhood vaccines 128 Section II of the hepatitis B vaccine market development of the market outlook analysis of 128 of China's hepatitis B status quo 128 Second, the hepatitis B vaccine Analysis of 130 college students hepatitis B vaccination in 130 four 131 five, 2012 China's hepatitis B vaccination progress, in 2012, China's hepatitis B Advances in Vaccine Research 132 six, 133 Section III of the hepatitis B vaccine industry trend analysis of rabies vaccine market 134, rabies overview of the 134 two 135 three rabies vaccine, rabies vaccine should be promptly injected 137 four rabies vaccine in 2012 to become a national regulatory focus 137 Section IV animal vaccine market analysis 138 First, the characteristics of China's animal vaccine industry 138 Second, the development status of China's animal vaccine industry 138 Third, the proposals of China's animal vaccine industry marketing 139 four, the growth potential of China's animal vaccine market analysis 140 five of animal opportunities for development of the vaccine industry analysis 141, the prospects for the development of China's animal vaccine market analysis 142 Section 5 Other vaccine market analysis 143 a 2012 meningitis vaccine market analysis 143 Second, the 2012 avian flu vaccine market analysis 145 III 2012 lung cancer vaccine Market Analysis 146 2012 hepatitis B tumor gene vaccine market analysis 146 V. 2012 domestic AIDS vaccine clinical study 147 VI, 149 seven of the live vaccine with the H5N1 avian influenza in 2012, 2012, China's cervical cancer vaccine into three 150 eight clinical trials developed in China in 2012, the third part of the success of the world's first H. pylori vaccine 151 industry competition pattern analysis of the competitive status quo of Chapter VII of the vaccine industry analysis 152 a 152 first section of China's bio-pharmaceutical production enterprises competitiveness analysis China's bio-pharmaceutical industry SWOT analysis 152 two, 154 three competitive factors promote the development of bio-pharmaceutical industry, the competitive status quo of the Biotechnology and Pharmaceutical Industry 163 four, the competitiveness of China's bio-pharmaceutical enterprises, biomedicine 163 key competitiveness of enterprises 165 Section II China's bio-pharmaceutical industry competitiveness upgrade path 165 a, 165 two of the current situation and ways of development of China's bio-pharmaceutical industry, biomedical industry development status and enhance 167 three biomedical industry innovation Countermeasures 167 Section III the domestic biopharmaceutical company competition pattern 169 a Competitive Analysis 169 Second, the competitive trend analysis of 170 competitive core analysis 172 171 Section IV of the vaccine market competition, China's vaccine market competition analysis 172 Second, the supply of the vaccine market competition analysis 174 Third, China's vaccine market competition pattern 174 Fourth, China's vaccine market competition, risk analysis 175 five, the vaccine market competition strategy analysis of 176 six, the domestic hepatitis A vaccine market competition analysis 177 Chapter VIII vaccine key manufacturers analysis of 179 first section of the Beijing Tiantan Biological Products Co., Ltd. 179 Company Profile 179 II, 179 three companies is operating in 2012, the 2012 financial data analysis 180 four 2012 companies develop dynamic 185 Section II of the Shanghai Institute of Biological Products 186, 186, 2012 Company Profile Company News 186 first three Shenzhen Kangtai Biological Pharmaceutical Co., Ltd. 188 Company Profile 188, 2012 News 188 Part IV of Changchun Changsheng Life Science and Technology Co., Ltd. 189 a Company Profile 189 II, company distribution network 190 Section V Animal Husbandry Industry Co., Ltd. Company 190 Company Profile 190 II, 2012 operating conditions of 193 three financial data for 2012 193 IV 2012 News 198 Section VI Inner Mongolia Jinyu Group 199 a Company Profile 199 II in 2012, the operating conditions of 202 three The 2012 financial data analysis 202 Fourth, in 2012, the company developing dynamic 208 Section VII China National Biotec Group 208 I. Company Profile 209 II, 209 Section VIII of the company's main business Hualan Biological Engineering Co., Ltd. 210 Company Profile 210 Second, the 2012 operating conditions of 210 three 2012 financial data analysis 210 four, Hualan income growth forecast 216 fourth part of the development of the industry forecast and strategy Chapter 217 Section I the 2012-2017 vaccine industry market forecast Ten Five-bio-pharmaceutical development planning 217 "12th Five-Year" development of vaccines and diagnostic reagents forecast 217 "12th Five-Year" development of innovative drugs predicted 217, "second five" modern traditional Chinese medicine development forecast 218 four, "Ten 25 "biomedical engineering development forecast in 2012-2017 218 Section II of the vaccine industry trend forecast 219 a vaccine R & D research direction predicted 219 Second, the Chinese vaccine market size in 2012 to predict 221, 221 the first of the future trends in the field of recombinant vaccines three 2012-2017 global vaccine industry development trends of the global vaccine market forecast for 223 ,2012-2017 223 ,2012-2017 global vaccine market forecast 225 Chapter 2012-2017 strategic analysis of investment opportunities in the vaccine industry 228 Section of China vaccine industry investment environment analysis 228 vaccine industry policy analysis 228 Second, the vaccine industry boom 228 Third, the potential demand of the vaccine industry analysis 229 Section II vaccine industry investment analysis 229, the investment advantages of the vaccine industry 229 two hot spot for investment in the field of biological vaccines analysis 230, the biological vaccine investment opportunities analysis 232 A 231 Section III of the vaccine industry, Investment Analysis, and foreign the vaccine market investment competition analysis 232 Second, the opportunity to analyze the profitability of the vaccine industry 234 Third, investment in the field of venture capital vaccine analysis 238 Part IV of the different varieties of the vaccine industry the opportunity to analyze 240, the influenza vaccines investment opportunity analysis 240 rabies vaccine investment opportunity analysis 242 Third, the investment opportunities of the hepatitis B vaccine in 243 four, the investment opportunities of the measles vaccine 244 five livestock vaccine investment opportunities. 244 Appendix 246 Appendix I: Distribution of Vaccines and vaccination regulations 246 Appendix II: Vaccination abnormal reaction identification approach 259 chart catalog chart: vaccinology - the initial stage of 8 Charts: vaccinology -1875 years of experience of World War I and to 1930 Chart 9: Vaccinology - transition influenza and adenovirus preparations and vaccines early study 10 chart: the modern period - bacterial capsular polysaccharide vaccine continued research and development - 1950 12 Chart: the modern period - viral vaccines - polio in 1950 13 Chart: modern period - the live virus vaccine in children - hinder 15 chart: the obvious problems and solutions of modern times - children with active virus vaccine - 15 Chart: 17 charts of the modern period - the Mo Ruike's Chicken cancer vaccine: Modern period-A hepatitis A virus vaccine 18 chart: modern-B virus vaccine during the 19 chart: 10 August 1999 -2012 industrial output monthly year-on-year growth rate (%) Chart 40: 2012 industrial output growth 40 chart speed: regional growth rate of industrial added value in October 2012 40 Chart: October 2012 Industry BigClass line value-added growth rate of 41 chart: October 2012 industrial output of major products and the growth rate of 43 chart: 1999 total retail sales of social consumer goods in August -2012 October monthly year-on-year growth rate (%) 46 Chart: Retail sales in January-October 2012 46 Chart: Consumer Price Index 47 chart in October 2012: October 2012 regional consumer price index (same period last year to 100) Chart 47: October 2012 Retail Price Index by Category 48 chart: Chart 49: Consumer Confidence Index, October 2012 to complete the amount of the investment in fixed assets in 1999 -2012 the monthly cumulative year-on-year growth rate (%) 50 Chart: 50 charts of urban fixed asset investment in January-October 2012: January to October 2012, various sectors of urban investment 51 charts: January to October 2012, the regional urban investment Chart 53: completion of the investment and growth of the real estate development enterprises in January-October 2012 54 Chart: Total Value of Import and Export trade patterns 56 chart in October 2012: the consumer price index in October 2012 (the same month last year = 100 ) 58 Chart: January 2012 -2012 October CPI & PPI Graph 59 Chart: data and policy 59 chart in January 2007 -2012 in October: the producer price index for August 1999 -2012 in October (on August 1999 -2012 in October, the same month = 100) 61 Chart: Monthly year-on-year growth rate of the money supply (%) 64 chart: 64 Chart macroeconomic climate index for October 2012: June 2012 -2012 in October macroeconomic climate index warning signal chart in Figure 65: December 1993 October -2012 macroeconomic climate index warning trend Figure 65 Chart: 2012 State Food and Drug Administration confirmed influenza vaccine manufacturers list 124 chart: 2012 Tiantan Biological Products Co., Ltd. Main constitute 180 chart :2009-2012 Beijing Tiantan Biological Products Co., Ltd. Table current assets 180 chart :2009-Beijing Tiantan Biological Products Co., Ltd. in 2012, long-term investment 181 chart :2009-2012 table in fixed assets of the Beijing Tiantan Biological Products Co., Ltd. 181 chart :2009-2012 Beijing Tiantan Biological Products Co., intangible and other assets Table 181 chart :2009-2012 current balance sheet, Beijing Tiantan Biological Products Co., Ltd. 181 chart: 2009 long-term liabilities -2,012 Beijing Tiantan Biological Products Co., Ltd. Table 181 chart :2009-2012 Beijing Tiantan Biological Products Co., Ltd. shareholders' equity 182 chart :2009-2012 main business income of the Beijing Tiantan Biological Products Co., Ltd. Table 182 chart :2009-2012, the main business of the Beijing Tiantan Biological Products Co., Ltd. Income Statement 182 chart :2009-Beijing Tiantan Biological Products Co., Ltd. in 2012 operating income by 182 chart :2009-2012 profit of Beijing Tiantan Biological Products Co., Ltd. Total Table Beijing Tiantan Biological Products Co., Ltd. Net profit 183 chart :2009-2012 Table 183 chart :2009-2012 Beijing Tiantan Biological Products Co., Ltd. per share indicators Table 183 chart :2009-2012 Beijing Tiantan Biological Products Co., Ltd. Company Profitability Table 183 chart :2009-2012, Beijing Tiantan Biological Products Co., Ltd. operating capacity table 184 chart :2009-2012, Beijing Tiantan Biological Products Co., Ltd. solvency Table 184 chart :2009-2012 Beijing Tiantan Biological Products Co., Ltd. Capital Structure Table Table 184 chart 184 chart :2009-2012 Beijing Tiantan Biological Products Co., Ltd. development capacity :2009-2012 Beijing Tiantan Biological Products Co., Ltd. Cash Flow Analysis Table 184 chart: Changchun Changsheng shares of biotechnology Limited distribution network 190 chart: Animal Husbandry Industry Co., Ltd. 2012 Main constitute 193 Chart :2009-2012 Animal Husbandry Industry Co., Ltd. Current assets table 194 chart :2009-2012 Animal Husbandry Industry Co., Ltd. long-term investment in Table 194 chart: Animal Husbandry Industry Co., Ltd. fixed assets Table 194 chart :2009-2012 Animal Husbandry Industry Co., Ltd. intangible and other assets table 194 chart :2009-2012 flow sheet of Animal Husbandry Industry Co., Ltd. in 2009-2012 195 chart :2009-2012 the annual Animal Husbandry Industry Co., Ltd. Long-term liabilities Table 195 chart :2009-2012, shareholders' equity of Animal Husbandry Industry Co., Ltd. Table 195 chart :2009-2012 Animal Husbandry Industry Co., Ltd. main business income statement 195 chart :2009-2012 Animal Husbandry Industry the Corporation main business income statement 196 chart :2009-Animal Husbandry Industry Co., Ltd. in 2012 operating income by 196 chart-table of the total profit of the Animal Husbandry Industry Co., Ltd. in 2012 196 Chart :2009-2012 China Animal Husbandry Industry Co., Ltd. net profit Table 196 chart :2009-2012 Animal Husbandry Industry Co., Ltd. per share Indicators Table 196 chart :2009-2012 Animal Husbandry Industry Co., Ltd. Profitability Table 197 chart :2009-2012 Animal Husbandry Industry Co., Ltd. operating capacity table Table 198 chart: 2009 197 chart :2009-2012 Animal Husbandry Industry Co., Ltd. solvency Table 197 chart :2009-2012 Animal Husbandry Industry Co., Ltd. Capital Structure Table 197 chart :2009-2012 Animal Husbandry Industry Co., Ltd. development capacity Animal Husbandry Industry Co., Ltd. -2012 Cash Flow Analysis Table 198 chart: 2012 Inner Mongolia Jinyu Group Co Ltd, Inner Mongolia constitute current assets 202 chart :2009-2012, Inner Mongolia Jinyu Group Co., Ltd. in Table 203 chart :2009-2012 of long-term investment Jinyu Group Co., Ltd. Inner Mongolia Jinyu Group Co., Ltd. 203 chart :2009-2012 fixed assets Table 203 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. intangible and other assets 204 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. Current liabilities Form 204 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. Long-term liabilities Table 204 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. shareholders' equity Table 204 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. Main business income chart in Table 205 :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. main business income statement 205 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. is operating income by 205 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. a total profit of 205 chart-table Inner Mongolia Jinyu Group Co., Ltd. in 2012 net profit of Table 206 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. per share indicators Table 206 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. Profitability Table the 206 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. viability of Table 206 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. solvency Table 207 chart :2009-2012 Inner Mongolia Jinyu the capital structure of the Group Co., Ltd. Table 207 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. development capacity table 207 chart :2009-2012 Inner Mongolia Jinyu Group Co., Ltd. Cash Flow Analysis Table 207 chart: 2012 Love Lan Biological Engineering Co., Ltd. the company Main constitute Biological Engineering Co., Ltd. 210 chart :2009-2012 Love Lan current assets Table 211 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. of fixed assets Bio-Engineering Co., Ltd. Table 211 chart :2009-2012 Love Lan invisible tables and other assets 212 chart :2009-2012 Love Lan Bioengineering Co. Current liabilities Table 212 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. of long-term liabilities 212 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. shareholders interest in table 212 chart :2009-2012 Love orchid Biological Engineering Co., Ltd. main business income Table 213 chart :2009-2012 Love Orchid Bio-Engineering Co., Ltd. main business income statement 213 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. Company operating income by 213 chart :2009-2012 Love Lan total profit of Bio-Engineering Co., Ltd. Table 213 chart :2009-2012 Love Lan Bioengineering Co. net profit Table 213 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. each shares Indicators Table 214 chart :2009-2012 Love Lan Bioengineering Co. Profitability Table 214 chart :2009-2012 Love Lan Bioengineering Co. viability of table 214 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. subordinated debt capacity table 214 chart :2009-2012 Love Lan Biological Engineering Co., Ltd. Capital Structure Table 215 chart :2009-2012 Love Orchid Bio-Engineering Co., Ltd. development capacity Table 215 chart :2009-2012 Love Orchid Bio-Engineering Co., Ltd. cash flow the analysis Table 215 chart: the global vaccine market growth trends Chart 223: 2007 with major vaccine manufacturers market share 22